Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study | Zendy

Avijit Hazra | Zendy; Ballari Brahmachari | Zendy; Anup Majumdar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study

Author(s) -

Avijit Hazra,

Ballari Brahmachari,

Anup Majumdar

Publication year - 2011

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.77341

Subject(s) - paclitaxel , observational study , drug , adverse effect , pharmacology , medicine , adverse drug reaction , chemotherapy

Conventional polyethoxylated castor oil (PCO)-based paclitaxel is associated with major adverse drug reactions (ADRs). Nanoxel, a nanoparticle-based formulation, may improve its tolerability by removing the need for PCO vehicle, and also permit its use in a higher dose. We conducted intensive monitoring of the ADR profile of Nanoxel in comparison with conventional paclitaxel in a public tertiary care set-up.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research